Clinical trials: DEB-TACE
Hepatocellular Carcinoma Non-resectable
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed…
- Trial name
- NCT06397235
- Testing
- DEB-TACE+HAIC, DEB-TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma, Liver Cancer
Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCC
BACKGROUND: Hepatocellular carcinoma is the fifth most frequent cancer in the world, with a diagnosis of more than 500,000 new cases per year.
- Trial name
- NCT04653701
- Testing
- Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Juan José Ciampi Dopazo
Hepatocellular Carcinoma (HCC), TACE
DEB-TACE vs cTACE in HCC After TIPS
This is a Phase 3, open-label, multicenter, randomized controlled clinical trial designed to evaluate the efficacy and safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) compared with Conventional…
- Conditions
- Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE
- Trial name
- UPGRADE (NCT07322848)
- Testing
- DEB-TACE, cTACE
- Where
- China
- Volunteers
- 206 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Intrahepatic Cholangiocarcinoma
A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC
At present, for advanced Intrahepatic Cholangiocarcinoma（ICC）, the effect of single treatment is not good.So far, superselective drug-eluting bead transarterial chemoembolization（DEB-TACE） is a good method for the treatment of…
- Trial name
- CCGLC-005 (NCT05236699)
- Testing
- DEB-TACE combined with Surufatinib and Camrelizumab
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
This study aimed to evaluate the efficacy and the safety of the anti-programmed-death-1 antibody (anti-PD-1) Sintilimab Injection in combination with transarterial chemoembolization with drug-eluting beads(TACE-DEB) in patients…
- Trial name
- NCT04174781
- Testing
- Sintilimab, DEB-TACE
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma
Role of DEB-TACE Versus c-TACE in Treatment of HCC
Hepatocellular carcinoma (HCC) is listed as the sixth most common cancer worldwide and the third most frequent cause of cancer-related mortality. The majority of HCC cases occurs stem from chronic liver disease and cirrhosis.
- Trial name
- NCT05093920
- Testing
- Doxorubicin-Eluting Beads
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
Hepatocellular Carcinoma
DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
This study will evaluate the safety and efficacy of DEB-TACE with visualable embolization microspheres versus PVA microspheres for hepatocellular carcinoma.
- Trial name
- NCT06190665
- Testing
- DEB-TACE with visualable microspheres, DEB-TACE with PVA microspheres
- Where
- 2 sites in China
- Volunteers
- 188 people
- Sponsor
- Zhongda Hospital
Liver Cancer
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to living donor liver transplantation can prolong the recurrence-free survival in patients with…
- Trial name
- NCT06353126
- Testing
- DEB-TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Liver Cancer
DEB-TACE Treatment in 367 Liver Cancer Patients
Introduction:The drug-eluting beads transarterial chemoembolization (DEB-TACE) is introduced to better improve efficacy and reduce the systemic toxicity in liver cancer patients on account of its higher intratumoral…
- Trial name
- NCT03317483
- Volunteers
- 367 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma (HCC)
Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. This type of cancer may be "hypervascular". Hypervascular means there is an increased number or concentration of blood vessels.
- Trial name
- NCT03452553
- Testing
- LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
- Sponsor
- Boston Scientific Corporation
Colorectal Cancer Metastatic
Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM
Retrospective evaluation of the efficacy and safety of DEB-TACE combined with HAIC versus HAIC alone in patients with unresectable colorectal liver metastases (CRLM)
- Trial name
- NCT07031570
- Volunteers
- 500 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
DEB-TACE for Hepatocellular Carcinoma
Patients enrolled in this study have been diagnosed with hepatocellular carcinoma (HCC) and are scheduled to have a procedure called drug-eluting bead trans-arterial chemoembolization (DEB-TACE).
- Trial name
- QED (NCT02748161)
- Testing
- DEB-TACE
- Where
- 11 sites in United States
- Volunteers
- 170 people
- Sponsor
- Surefire Medical, Inc.
Liver Cancer
A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
The purpose of the study is to find out the effects of using nivolumab with Drug Eluting Bead Transarterial Chemoembolization (deb-TACE) in the treatment of liver cancer.
- Trial name
- NCT03143270
- Testing
- Drug Eluting Bead Transarterial Chemoembolization, Nivolumab
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Surefire Precision Infusion System Registry
This project involves the collection and analysis of retrospective and prospective data on patients diagnosed with hepatocellular carcinoma (HCC) in which the Surefire Precision Infusion System was used/will used be to deliver…
- Trial name
- NCT02967523
- Testing
- DEB-TACE with Surefire Precision Infusion System
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- Surefire Medical, Inc.
Hepatocellular Carcinoma
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low after DEB-TACE treatment.
- Trial name
- NCT04229355
- Testing
- DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above.
- Conditions
- Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib, PD-1 Antibody
- Trial name
- NCT04834674
- Testing
- DEB-TACE combined with apatinib and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Unresectable Hepatocellular Carcinoma
DEB-TACE+HAIC vs. HAIC for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) plus hepatic artery infusion chemotherapy (HAIC) compared with HAIC alone for unresectable large…
- Trial name
- NCT05263219
- Testing
- dTACE-HAIC, HAIC, dTACE-HAIC protocol
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Liver Cancer
Prospective Liver Study
This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.
- Trial name
- NCT01539993
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Emory University
Hepatocellular Carcinoma
A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
The aim of this study is to clarify the safety and efficacy of DEB-TACE combined with SALOX-HAIC in the treatment of unresectable advanced primary liver cancer.
- Trial name
- NCT06823050
- Where
- 7 sites in China
- Volunteers
- 59 people
- Sponsor
- Xuhua Duan
Hepatocellular Carcinoma
Surefire Institutional DEB-TACE
The purpose of this study is to determine the feasibility and safety of the Surefire Infusion System (SIS) for delivery of Drug Eluting Beads Transcatheter Chemoembolization (DEB-TACE) in the HCC population.
- Trial name
- NCT03211598
- Testing
- TACE with Surefire
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Alexander Kim